Jaundice, ascites, and encephalopathy Flashcards
Causes of jaundice
Pre-hepatic
- Gilbert’s syndrome
- Hemolysis
- Hematoma
Hepatic
- Tumour infiltration
- Viral hepatitis (may become reactivated while on chemo or immunosuppressive therapy e.g. dex)
- Drug toxicity (acetaminophen, alcohol)
- Cholestasis (drugs, septicemia)
- GVHD
- Venous outflow block (severe heart failure, budd chiari)
Post-hepatic
- Malignant (pancreatic ca, cholangioca, lymphadenopathy
- Gallbladder/bile duct issues (gallstones, chronic pancreatitis, biliary stricture)
Gilbert’s syndrome
- Inherited disorder resulting in a deficiency of an enzyme normally used to break down bilirubin in the liver, which results in more unconjugated bilirubin circulating
- Mild, chronic unconjugated hyperbilirubinemia in the absence of liver disease or hemolysis
- Elevated bilirubin levels in response to stresses (fasting, comorbidity, infection, treatment for malignancy)
- May be more vulnerable to toxic side effects with certain chemotherapies
Viral hepatitis in palliative care
- Watch for reactivation of infection related to use of corticosteroids or cytotoxic regimens!
Drug-induced liver disease
- May be both hepatocellular (death of hepatocytes) and cholestatic
Hepatocellular reactions
- Allopurinol
- Herbal remedies
- Halothane
- Minocycline
- Phenytoin
Cholestatic/mixed reactions
- Amox/clav
- Chlorpromazine
- Levomepromazine
- Erythromycin
- TCAs
- Fluoxetine
- Acetylcholinesterase inhibitors
- Enzyme levels typically return to normal after withdrawal of the offending agent (50% by 2 weeks, normalisation by 4 weeks), though cholestatic injury may be more chronic
- Little evidence of increased risk in drug-related hepatotoxicity in patients with pre-existing disease, though slowed metabolism puts them at higher risk of systemic drug toxicity
Pathophysiology of sepsis and jaundice
- Cholestatic, non-obstructive jaundice may occur in sepsis or shock
- Cholestasis due to hypotension, low hepatic blood flow
- Direct inhibition of bile secretion by endotoxin and inflammatory cytokines
Pathophysiology of cardiac failure and the liver
- Rare presentation of CHF, but altered liver function common in advanced CHF
- Due to sinusoidal congestion (results in cholestatic picture with elevated ALP, GGT). Most pronounced in TR.
- Significant hypotension may also result in ischemic hepatitis with very high enzymes (‘shock liver’)
Pathophysiology of Budd-chiari, associations and tx
- Jaundice due to venous occlusion of the hepatic vein
- May be rapid onset or more chronic
- Typical presentation with abdo pain, ascites, hepatomegaly, signs of GI bleeding
Associated with a hypercoagulable state:
- Myeloproliferative disorders
- Polycythemia rubra vera
- Essential thrombocytosis
- Malignancy
Management:
- Correct underlying disorder if possible
- Anticoags, assuming no contraindications (varices!!!!)
- If symptomatic, consult for angiography, stenting, thrombolysis, TIPS
Etiology of obstructive jaundice
- Obstruction of the biliary tract at any point from within the liver to the ambulla of vater
- Gallstones
- Pancreatic ca
- Cholangio ca
- Metastatic ca
- HCC
Note that malignant obstructions are not necessarily painless
Symptoms related to jaundice
- Pruritis
- Nausea
- Indigestion
- Sleep impairment
- Encephalopathy
Workup of jaundice
History PE - Signs of portal hypertension - Intra abdo malignancy - HE (orientation, asterixis)
Labs
- LFTs, INR, CBC (infective cholangitis)
Significance of isolated ALP
- Isolated elevation unusual, may reflect bone disease
Clinical chacteristics of hemolytic jaundice (presentation, LFTs, US findings)
Presentation
- Asymptomatic or backache, arthralgia
- Splenomegaly
LFTs
- Bili <100
Normal ALT, ALP, INR
US
- no dilated bile ducts
Clinical characteristics of hepatocellular jaundice (presentation, LFTs, US findings)
Presentation
- N/V, anorexia, pyrexia
- Tender hepatomegaly
LFTs
- Bili variable
- ALT >5x
- ALP 2-3x
- elevated INR (not corrected by vit K)
US
- no dilated bile ducts
Clinical characteristics of intrahepatic cholestasis (presentation, LFTs, US findings)
Presentation
- Deep jaundice
- Dark urine, light stools
- Pruritis
- Tender hepatomegaly
LFTs
- Bili variable, but may be >500
- 2-5x ALT
- 3-5x ALP
- long INR, may be corrected by Vit K (depending on hepatocellular disease)
US
- no dilated bile ducts
Clinical characteristics of post hepatic cholestasis/obstructive jaundice (presentation, LFTs, US findings)
Presentation
- Deep jaundice
- Dark urine, light stools
- Pruritis, cholangitis
- Biliary cholic
- Hepatomegaly, palpable gallbladder
LFTs
- Bili < 500
- ALT 2-5x
- ALP 3-5x
- elevated INR (corrects with vit K)
US
- Dilated bile ducts
How to differentiatel intrahepatic cholestasis from post hepatic cholestasis
In post-hepatic cholestasis, more likely to have palpable gall bladder, INR correctable with Vit K (impaired intestinal absorption of fat soluble vitamins rather than hepatocellular disease), and dilated bile ducts on US
Imaging for jaundice
US
- Cheap and bedside
- Useful for detecting biliary duct dilatation, but limited in obese patients
CT
- can detect and characterise smaller lesions, stage disease
MRCP
- Differentiate benign versus malignant lesions
- Avoids risks associated wtih ERCP
ERCP
- Allows for imaging, cytology, and dilatation/stent insertion if drainage of the biliary system is required
- Risks include cholangitis, bleeding, bile duct leakage, acute pancreatitis
Management of jaundice
- Chemo for sensitive malignancies
- Biliary drainage procedures may provide rapid relief of pruritis, pain, nausea, anorexia, and QOL
Biliary drainage procedures
ERCP with stent
- stents inserted endoscopically, if at the low CBD
- Failure rate 30-40% plastic stents, 10-15% with metallic
- Higher rates of cholangitis with plastic stents
- If stents occlude, can be replaced (plastic) or have patency restored (metallic)
Percutaneous transhepatic biliary drainage
- Used if level of biliary obstruction is high (proximal to common bile duct) or there is distorted anatomy (prev surgery, local tumour)
- Also second line if ERCP fails
Presentation of cholestatic pruritis
- Itch does not tend to correlate with serum bilirubin levels or stage of chronic liver disease
- Typically starts on palms and soles before becoming more generalised
- Circadian rhythm, worst between 1200 and 1800 hours
Pathophysiology of pruritis in jaundice
- Bile acid accumulation may be pruritogenic (however pruritis does not correlate with bilirubin levels)
- May be due to central neural mechanisms from alterations in endogenous opioids, serotonin, and GABA
Opioid system
- Endogenous opioid levels are elevated in patients with CLD
- Activation of central/peripheral kappa opoid receptors may inhibit itch
- Activation of mu-receptors may contribute to itch (antagonised by naloxone)
Serotoninergic system
- Thought to be involved due to close links between serotonergic and opioidergic transmission systems
Lysophosphatidic acid and autotaxin
- High levels of lysophosphatidic acid in the serum of individuals with cholestatic itch, with levels correlating to severity
- Autotaxin is an enzyme involved in the production of active lysophosphatidic acid
Management of Cholestatic pruritis:
Mild
- Consider emollients, warm baths
- May try antihistamines at night, but not likely to be very effective
Moderate to severe:
- Bile acid sequestrant (cholestyramine, TDD 4-16g)
- If ineffective, switch to rifampin 150-300mg PO BID (reduces autotaxin expression)
If ineffective:
- naltrexone 12.5 - 50mg PO daily (note cannot give if patients is on opioid tx or in active liver failure)
- sertraline 75mg PO daily
Non-pharmacologic management of pruritis
- Keep fingernails cut short and wear cotten gloves at night to reduce skin damage
Unclear evidence:
- Topical emollients
- Stay cool, lessen sweating
Malignancies most commonly associated with ascites
- Ovarian CA (most common)
- Breast
- Colonic CA
- Gastric ca
- Pancreatic CA
- CUP